Projects per year
Personal profile
Area of Expertise
The general research area of Dr. Mathew’s laboratory is Cancer Immunology. His research focuses on the Cellular and Molecular Biology of human natural killer (NK) cells and their recognition by cancer cells. NK cells are a subpopulation of lymphocytes that play an important role against cancer and various viral and bacterial infections.
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.
Education/Academic qualification
PhD in Biochemistry, University of Poona
Award Date: 1 Jan 2002
MS in Biochemistry, University of Poona
Award Date: 1 Jan 2001
BS in Physics, University of Kerala
Award Date: 1 Jan 2000
Fingerprint Dive into the research topics where Porunelloor Mathew is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 6 Finished
Exosomal-Annexin A2 Promotes Metastasis in Triple-negative Breast Cancer
1/06/17 → 31/05/18
Project: Research
Molecular Characterization of NKp44 Ligand on Astrocytes
NINDS: Neurological Disorders & Stroke
1/02/17 → 31/01/19
Project: Research
CS1-Targeted Immunotherapy for Acute Lymphoblastic Leukemia (ALL) in Children
Mathew, S., Mathew, P. & Bowman, P.
1/09/13 → 31/08/15
Project: Research
Research Output
2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer
Malaer, J. D., Marrufo, A. M. & Mathew, P. A., Jul 2019, In : Clinical Immunology. 204, p. 50-56 7 p.Research output: Contribution to journal › Review article
A novel ligand on astrocytes interacts with natural cytotoxicity receptor NKp44 regulating immune response mediated by NK cells
Bowen, K. E., Mathew, S. O., Borgmann, K., Ghorpade, A. & Mathew, P. A., Feb 2018, In : PLoS ONE. 13, 2, e0193008.Research output: Contribution to journal › Article
1
Scopus
citations
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma
Malaer, J. D. & Mathew, P., 1 Jan 2017, In : American Journal of Cancer Research. 7, 8, p. 1637-1641 5 p.Research output: Contribution to journal › Review article
Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells
Kim, J. R., Mathew, S. O. & Mathew, P., 1 Jan 2016, In : Immunobiology. 221, 1, p. 31-39 9 p.Research output: Contribution to journal › Article
7
Scopus
citations
Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction
Mathew, S. O., Chaudhary, P., Powers, S. B., Vishwanatha, J. K. & Mathew, P. A., 1 Jan 2016, In : Oncotarget. 7, 42, p. 68650-68661 12 p.Research output: Contribution to journal › Article
10
Scopus
citations